CRL vs. JAZZ: Charles River Laboratories vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Jazz Pharmaceuticals (JAZZ) is defensive at 0.33 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Charles River Laboratories (CRL) at 1.27% and Jazz Pharmaceuticals (JAZZ) at 5.05% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Charles River Laboratories (CRL) at 1.01% and Jazz Pharmaceuticals (JAZZ) at 4.37% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Charles River Laboratories (CRL) at 23.42% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Jazz Pharmaceuticals (JAZZ) at 4.88% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither side shows strong earnings momentum: Jazz Pharmaceuticals (JAZZ) at -167.51% sits in the bottom EPS growth quartile, and Charles River Laboratories (CRL) at -1,555.00% is weaker still, below its industry range.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Charles River Laboratories (CRL) at 0.87 and Jazz Pharmaceuticals (JAZZ) at 1.35 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Charles River Laboratories (CRL) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer P/E ratio quartile, and Charles River Laboratories (CRL) at 366.87 is richer still, above its industry range.

On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics